Doxycycline 7 days
PreclinicalSmall molecule
Doxycycline 7 days is one of 30 small molecule programs targeting Erythema. It is currently in Preclinical.
2
Indications
5
Total Trials
2
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Dermatitis
#DrugCompanyPhaseTrials
1Otezla
AmgenApproved
Daliresp
AstraZenecaApproved
Anzupgo
Jazz PharmaceuticalsApproved
Nizoral
WWim Janssens
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rinvoq
AbbViePhase 1
JAK Inhibitor
FFred Hutchinson Cancer Center
Phase 2
Acanya
PfizerPreclinical
Voltaren
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Doxycycline 7 days. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details